Compass therapeutics presents data on enhanced efficacy of ctx-471 in combination with tovecimig in checkpoint-refractory models at the american association for cancer research (aacr) annual meeting

Ctx-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. combining ctx-471 with tovecimig (ctx-009) markedly increased anti-tumor efficacy in these models.

CMPX Ratings Summary

CMPX Quant Ranking